Kuliev A, Rechitsky S, Verlinsky O, Ivakhnenko V, Evsikov S, Wolf G, Angastiniotis M, Georghiou D, Kukharenko V, Strom C, Verlinsky Y
Reproductive Genetics Institute, Chicago, Illinois 60657, USA.
J Assist Reprod Genet. 1998 May;15(5):219-25. doi: 10.1023/a:1022571822585.
Preimplantation genetic diagnosis (PGD) is an important option for couples at risk of having children with beta-globin mutations to avoid selective abortions of affected fetuses following prenatal diagnosis.
We performed PGD for thalassemia in 12 clinical cycles (IVS1-110, and IVS-745 mutations) using biopsy of the first and second polar bodies (PBs) extruded from oocytes during maturation and fertilization, coupled with nested polymerase chain reaction analysis and restriction digestion.
A total of 118 oocytes was obtained, of which 78 had results for both the first and the second PBs. This resulted in the selection and transfer of 30 unaffected embryos (2.5 embryos per cycle). To avoid a possible misdiagnosis due to allele dropout (ADO), we have also introduced simultaneous detection of two highly polymorphic linked markers, a short tandem repeat immediately at the 5' end of the globin gene and HUMTH01 which is a syntenic short tandem repeat. The application of multiplex polymerase chain reaction of the beta-globin gene and linked polymorphic markers enabled detection of ADO in five first PBs, thus avoiding the transfer of potentially affected embryos resulting from their corresponding oocytes.
Confirmation studies of the embryos resulting from the oocytes predicted to contain an affected gene confirmed the diagnosis in 98% of the cases, thus demonstrating the accuracy and reliability of PB PGD of thalassemia mutations. The application of PB analysis in six patients resulted in two ongoing pregnancies with a thalassemia-free fetus already confirmed in both of them by prenatal diagnosis.
胚胎植入前遗传学诊断(PGD)是有生育β-珠蛋白基因突变患儿风险的夫妇避免产前诊断后选择性终止受影响胎儿妊娠的重要选择。
我们对12个临床周期(IVS1-110和IVS-745突变)的地中海贫血进行了PGD,采用在卵母细胞成熟和受精过程中挤出的第一极体和第二极体(PBs)活检,结合巢式聚合酶链反应分析和限制性消化。
共获得118个卵母细胞,其中78个第一极体和第二极体均有结果。这导致选择并移植了30个未受影响的胚胎(每个周期2.5个胚胎)。为避免因等位基因脱失(ADO)导致的可能误诊,我们还引入了同时检测两个高度多态性连锁标记,即珠蛋白基因5'端紧邻的短串联重复序列和同源短串联重复序列HUMTH01。β-珠蛋白基因和连锁多态性标记的多重聚合酶链反应应用能够检测5个第一极体中的ADO,从而避免移植由其相应卵母细胞产生的潜在受影响胚胎。
对预计含有受影响基因的卵母细胞产生的胚胎进行的验证研究在98%的病例中证实了诊断,从而证明了地中海贫血突变的极体PGD的准确性和可靠性。对6名患者应用极体分析导致2例持续妊娠,产前诊断已证实两者胎儿均无地中海贫血。